All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
Did you miss ASH 2020? The AML Hub was pleased to virtually attend the 62nd ASH Annual Meeting & Exposition, December 5-8 2020, and has developed a downloadable resource on the practice-changing abstracts in acute myeloid leukemia (AML).
In this resource, you will find comments from the AML Hub Steering Committee members on improving frontline treatment for patients who are eligible and ineligible for chemotherapy, management of high-risk AML in the era of targeted therapies, maintenance, and novel targeted combinations and how they should be sequenced.
ASH 2020 | Practice-changing abstracts in acute myeloid leukemia
If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource below.Download here
What results are needed prior to therapy initiation in newly diagnosed AML?
Finally, the committee discusses the need for measurable residual disease (MRD) testing prior to initiation of therapy, highlighting recent data and the impact on...
What has ASH 2020 taught us about advancing frontline chemotherapy in AML?
Increased understanding of the driving genetic and epigenetic factors of acute myeloid leukemia (AML) in recent years has helped to refine novel chemotherapy combinations in...
Subscribe to get the best content related to AML delivered to your inbox